Bristol-Myers Squibb Stock - Insider option exercise adds to board holdings

Bristol-Myers Squibb sees fresh insider activity as director Julia A. Haller exercises stock options and holds the acquired shares. On this Wednesday we also look at the group’s current operational backdrop and strategy in oncology and immunology.

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 19:41 CEST. Details in the imprint.

Bristol-Myers Squibb (US1078421011) has reported fresh insider activity in its stock. According to a Form 4 filing with the U.S. Securities and Exchange Commission, board member Julia A. Haller recently exercised stock options and retained the resulting shares.

What the SEC filing shows

According to a recent Form 4 summarized by StockTitan, director Julia A. Haller exercised options for 20,460 Bristol-Myers Squibb shares at an exercise price of $53.76 on 06/15/2026 and chose to hold all acquired shares rather than sell them. The Form 4 overview highlights the transaction details.

Following this transaction, Haller’s direct ownership rose to 34,079 Bristol-Myers Squibb shares, while the option grant covering the 20,460 shares has now been fully exercised. Such insider moves are routinely disclosed but are often closely watched as a signal of management’s long-term alignment with shareholders.

Operations and strategy backdrop

Operationally, Bristol-Myers Squibb continues to focus on specialty medicines across oncology, hematology, immunology and cardiovascular disease, anchored by blockbuster therapies such as Eliquis and Opdivo. The group has emphasized a pipeline-driven strategy with a series of recent product launches and late-stage candidates.

Analysts tracking the company point to the ongoing patent cliff on older products but also to a growing contribution from newer drugs, including cell therapies and targeted oncology agents, which are intended to support revenue beyond this decade. Management has repeatedly underlined disciplined capital allocation between R&D, bolt-on M&A and shareholder returns in its recent investor presentations.

How the company makes money

Bristol-Myers Squibb generates most of its revenue from prescription medicines in oncology, hematology, immunology and cardiovascular indications, with Eliquis, the oral anticoagulant co-developed with Pfizer, and Opdivo, an immuno-oncology therapy, among its largest global products.

Where the stock trades today

The shares of Bristol-Myers Squibb (US1078421011) trade on the New York Stock Exchange at $57.60 as of 06/17/2026, 17:30 ET.

Key facts on Bristol-Myers Squibb stock

• Company: Bristol-Myers Squibb Company
• ISIN: US1078421011
• WKN: 850501
• Ticker: BMY
• Venue: NYSE
• Price (as of 06/17/2026, 17:30 ET): 57.60 USD
• Market cap: 116,000,000,000 USD (as of 06/17/2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: 07/24/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.